NEW YORK CITY, NY / ACCESS Newswire / June 5, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abivax S.A. ("Abivax" or "the Company") (NASDAQ:ABVX). Investors who purchased Abivax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ABVX.

Abivax Investigation Details

On June 2, 2026, Abivax announced results from its Phase 3 ABTECT clinical trial evaluating obefazimod for the treatment of ulcerative colitis, revealing rare cases of malignancy among trial participants. Following this news, Abivax's stock price dropped.

What's Next for Abivax Investors?

If you are aware of any facts relating to this investigation or purchased Abivax securities, you can assist this investigation by visiting the firm's site: bgandg.com/ABVX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Abivax Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Abivax Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

COMTEX_483088749/2457/2026-06-05T11:00:13